ProCE Banner Activity

Expert Guidance for Managing Triple Class–Refractory MM (Excluding BCMA-Targeted Therapies)

Slideset Download
Download this slideset based on content from the annual CCO/IMF satellite symposium at ASH on treatment options for patients with heavily pretreated, relapsed/refractory multiple myeloma, excluding BCMA-targeted agents.

Released: December 15, 2021

Expiration: December 14, 2022

Share

Faculty

Brian Hoyle

Brian Hoyle

Contributing Editor

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

GlaxoSmithKline

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Oncopeptides

Pfizer, Inc.

Sanofi Genzyme

Partners

International Myeloma Foundation

ProCE Banner